THE LOWEST ABILIFY ONLINE PRICE GUARANTEED, discreet delivery

Vision Shopsters: Neurodegenerative Market Forecast to 2013

Which Alzheimer's blockbuster faces diminishing sales within the next decade? What has the potential to take its place? Which class of MS drugs is emerging as successful? What innovative treatments are on the horizon? Who is on track to become a market leader? Neurodegenerative Market Forecast to 2013 answers these questions - and much more - so you can navigate the still-uncharted market landscape with ease. This overview is comprehensive, covering only the most relevant information on Alzheimer's, MS and Parkinson's.....all in one place. With in-depth brand and drug class analyses, make research and spending decisions with the utmost confidence. Other reports skim the surface, examining only top drugs at top companies. Ours is complete, covering marketed brands, pipeline products, clinical development, and whole drug classes. Find all you need to tap into or maximize your presence in this lucrative space.

Trend Towards Cheap Generic Drugs Continues

The IMS Institute for Healthcare Informatics has released a report on the most widely-used prescription drugs in the US in 2010. The Institute, an initiative of IMS Health, was established early in 2011 to strengthen global healthcare collaboration and "to work in tandem with government agencies, academic institutions, the life sciences industry and payers to drive a research agenda dedicated to addressing today's healthcare challenges".

The IMS report underlines the continuance of a major trend towards generic drugs over brand names, with 78 percent of the year's 4 billion prescriptions written for generic medications. Not surprisingly, the widely prescribed generic drugs are not the drugs generating the most money for the pharmaceutical companies. The top money makers are brand name prescription drugs of which generic versions are not yet available. The report noted that generic drug substitution for brand name drugs whose patents expired cost pharmaceutical companies $12.5 billion in 2010.